The COVID-19 vaccination program has probably been the most complex and extensive project in history until now, which has been a challenge for all the people involved in the planning and management of this program. Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy have required special attention, not only because of the particular haste in carrying out the process but also because of the uncertainty regarding their response to the vaccines. We now have strong scientific evidence that supports the hypothesis that immunosuppressive therapy inhibits the humoral response to vaccines against other infectious agents, such as influenza, pneumococcus and hepatitis B. This has led to the hypothesis that the same could happen with the COVID-19 vaccine. Several studies have therefore already been carried out in this area, suggesting that temporarily discontinuing the administration of methotrexate for 2 weeks post-vaccination could improve the vaccine response, and other studies with various immunosuppressive drugs are in the same line. However, the fact of withholding or interrupting immunosuppressive therapy when dealing with COVID-19 vaccination remains unclear. On this basis, our article tries to compile the information available on the effect of immunosuppressant agents on COVID-19 vaccine responses in patients with IMIDs and proposes an algorithm for the management of these patients.
Background/Objectives: Immunotherapy using immune checkpoint inhibitors has transformed the treatment of multiple solid tumours. However, the clinical response to programmed death receptor (PD-1) and its ligand (PD-L1) inhibitors remains heterogeneous. We have previously shown that host-related factors such as body mass index (BMI) may modulate the efficacy of immunotherapy. The aim of this study was to determine whether body composition, measured with bioelectrical impedance analysis (BIA) before treatment initiation, is a prognostic factor for survival outcomes in patients treated with PD-1/PD-L1 inhibitors, independently of tumour type and stage. Methods: In this prospective, single-centre observational study, patients with solid tumours underwent baseline body composition assessment using multifrequency bioelectrical impedance analysis (BIA) before initiation of PD-1/PD-L1 inhibitor therapy. Overall survival (OS), progression-free survival (PFS), and treatment-related adverse events were evaluated using Kaplan–Meier analyses and multivariable Cox regression models adjusted for tumour stage and metastatic status. Results: A total of 80 patients with solid tumours were included in the study. The median age was 67 years, and 48 (60.0%) were male. Higher BMI (≥25 kg/m2) and elevated body fat percentage (%BF) were associated with more favourable survival outcomes. After adjustment for tumour stage and metastatic status, BMI ≥ 25 kg/m2 was associated with a lower risk of death (HR 0.286, 95% CI 0.087–0.941; p = 0.039). Similar results were observed for elevated %BF (HR 0.289, 95% CI 0.087–0.963; p = 0.036). Neither BMI nor %BF was significantly associated with the occurrence of confirmed immune-related adverse events. Conclusions: Baseline BMI and body fat percentage were associated with survival outcomes in this exploratory cohort of patients receiving PD-1/PD-L1 inhibitors. These findings should be considered exploratory and hypothesis-generating and require confirmation in larger, tumour-specific prospective studies.